CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 22 enrolled
Drug / intervention
Fluticasone propionate inhaler +1 moredrug
Likely dose
Fluticasone propionate inhaler 250 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02338362
NCT02338362Phase 4Completed
CompareCT.gov

The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma.

University Health Network, Toronto·interventional·Posted Jan 14, 2015·Updated May 3, 2019

In Brief

A Phase 4 clinical trial evaluating Fluticasone propionate inhaler and Saline placebo inhaler for Ocular Hypertension and Glaucoma, Open-Angle. Completed, enrolled 22 participants.

Detailed Summary

The purpose of this study is to determine whether a commonly prescribed orally inhaled corticosteroid treatment will induce a clinically meaningful elevation in intraocular pressure, when administered to patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). Based on the response to high-dose corticosteroids, this patient group is more likely than the normal population to demonstrate this adverse effect.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Glaucoma, Open-Angle
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 14, 2015
Enrollment StartSep 1, 2014
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.5 years ago

Interventions

Fluticasone propionate inhalerdrug

fluticasone propionate 250 µg metered-dose inhaler

Saline placebo inhalerdrug

saline metered dose inhaler